Analytical Data
-
Gene name
MICA
- Application
-
Alternative Names
FLJ60820; MGC111087; MICA; PERB11.1; DAMA-345G11.2; FLJ36918; FLJ60820; MGC21250
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96QC4
-
Expression Region
E24-Q308
-
Molecular Weight
90-110 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MICA (MHC class I polypeptide-related sequence A) is a pivotal molecule involved in the immune system's recognition of stressed or transformed cells. MICA, a member of the MHC superfamily, plays a critical role in activating natural killer (NK) cells and CD8+ T cells by interacting with the NKG2D receptor on these immune effector cells. The study of MICA and its recombinant proteins has gained prominence due to its association with cancer progression, viral infections, and autoimmune diseases. Abnormal expression of MICA can serve as a biomarker for various malignancies, making it an attractive target for therapeutic interventions. Researchers have focused on producing recombinant MICA proteins to better understand its structure-function relationships and the dynamics of its interactions with immune cells. Such studies can elucidate MICA's role in tumor immune evasion and inform the development of MICA-based immunotherapies. Furthermore, recombinant MICA proteins can be utilized in diagnostic assays and therapeutic applications, highlighting the molecule's potential as a novel target in cancer immunotherapy and precision medicine. The investigation into MICA’s functional mechanisms continues to advance our understanding of immune regulation and the complexities of tumor-immune interactions, paving the way for innovative treatment strategies.
